AI Article Synopsis
- The effectiveness of denosumab, when used alongside hormonotherapy in breast cancer patients, was assessed through two studies (ABCSG-18 and D-Care), but the results concerning disease-free survival were inconsistent.
- The ABCSG-18 trial successfully met its main objective, which was to prevent clinical fractures in patients.
- Denosumab has been confirmed to protect against bone fragility caused by estrogen deprivation in the context of breast cancer, building on previous findings in post-menopausal women.
Article Abstract
The efficacy of adjuvant denosumab in combination with hormonotherapy in breast cancer patients was investigated in two randomized trials, ABCSG-18 and D-Care, but the results were mixed with respect to the impact of this drug on disease-free survival. However, the ABCSG-18 study has achieved its primary goal: prevention of clinical fractures. Therefore, the protective role of Denosumab on bone fragility induced by estrogen deprivation, already demonstrated in post-menopausal women, has been validated in the breast cancer setting.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11570850 | PMC |
| http://dx.doi.org/10.1016/j.breast.2024.103826 | DOI Listing |
Publication Analysis
Top Keywords
adjuvant denosumab
8
breast cancer
8
denosumab early
4
early breast
4
breast cancer-evidence
4
cancer-evidence controversy
4
controversy efficacy
4
efficacy adjuvant
4
denosumab combination
4
combination hormonotherapy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!